PMID- 9674752
OWN - NLM
STAT- MEDLINE
DCOM- 19980805
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 101
IP  - 4
DP  - 1998 Jun
TI  - Generation and functional characterization of human dendritic cells derived from 
      CD34 cells mobilized into peripheral blood: comparison with bone marrow CD34+ 
      cells.
PG  - 756-65
AB  - Dendritic cells (DCs) are the most powerful professional antigen-presenting cells 
      (APC), specializing in capturing antigens and stimulating T-cell-dependent 
      immunity. In this study we report the generation and characterization of 
      functional DCs derived from both steady-state bone marrow (BM) and circulating 
      haemopoietic CD34+ cells from 14 individuals undergoing granulocyte 
      colony-stimulating factor (G-CSF) treatment for peripheral blood stem cells 
      (PBSC) mobilization and transplantation. Clonogenic assays in methylcellulose 
      showed an increased frequency and proliferation of colony-forming unit-dendritic 
      cells (CFU-DC) in circulating CD34+ cells, compared to that of BM CD34+ 
      precursors in response to GM-CSF and TNF-alpha with or without SCF and FLT-3L. 
      Moreover, peripheral blood (PB) CD34+ cells generated a significantly higher 
      number of fully functional DCs, as determined by conventional mixed lymphocyte 
      reactions (MLR), than their BM counterparts upon different culture conditions. 
      DCs derived from mobilized stem cells were also capable of processing and 
      presenting soluble antigens to autologous T cells for both primary and secondary 
      immune response. Replacement of the early-acting growth factors SCF and FLT-3L 
      with IL-4 at day 7 of culture of PB CD34+ cells enhanced both the percentage of 
      total CD1a+ cells and CD1a+ CD14- cells and the yield of DCs after 14 d of 
      incubation. In addition, the alloreactivity of IL-4-stimulated DCs was 
      significantly higher than those generated in the absence of IL-4. Furthermore, 
      autologous serum collected during G-CSF treatment was more efficient than fetal 
      calf serum (FCS) or two different serum-free media for large-scale production of 
      DCs. Thus, our comparative studies indicate that G-CSF mobilizes CD34+ DC 
      precursors into PB and circulating CD34+ cells represent the optimal source for 
      the massive generation of DCs. The sequential use of early-acting and 
      intermediatelate-acting colony-stimulating factors (CSFs) as well as the use of 
      autologous serum greatly enhanced the growth of DCs. These data may provide new 
      insights for manipulating immunocompetent cells for cancer therapy.
FAU - Ratta, M
AU  - Ratta M
AD  - Institute of Haematology and Medical Oncology Seragnoli, University of Bologna, 
      Italy.
FAU - Rondelli, D
AU  - Rondelli D
FAU - Fortuna, A
AU  - Fortuna A
FAU - Curti, A
AU  - Curti A
FAU - Fogli, M
AU  - Fogli M
FAU - Fagnoni, F
AU  - Fagnoni F
FAU - Martinelli, G
AU  - Martinelli G
FAU - Terragna, C
AU  - Terragna C
FAU - Tura, S
AU  - Tura S
FAU - Lemoli, R M
AU  - Lemoli RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, CD34)
RN  - 0 (Membrane Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Stem Cell Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (flt3 ligand protein)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 207137-56-2 (Interleukin-4)
RN  - 6WS4C399GB (Lenograstim)
SB  - IM
MH  - Adjuvants, Immunologic/therapeutic use
MH  - Antigens, CD34/*metabolism
MH  - Bone Marrow Cells/*cytology
MH  - Cell Differentiation
MH  - Cell Division
MH  - Cells, Cultured
MH  - Dendritic Cells
MH  - Granulocyte Colony-Stimulating Factor/therapeutic use
MH  - Hematopoietic Stem Cell Mobilization
MH  - Hematopoietic Stem Cells/cytology
MH  - Humans
MH  - Interleukin-4/pharmacology
MH  - Lenograstim
MH  - Membrane Proteins/pharmacology
MH  - Recombinant Proteins/therapeutic use
MH  - Stem Cell Factor/pharmacology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 1998/07/23 00:00
MHDA- 1998/07/23 00:01
CRDT- 1998/07/23 00:00
PHST- 1998/07/23 00:00 [pubmed]
PHST- 1998/07/23 00:01 [medline]
PHST- 1998/07/23 00:00 [entrez]
AID - 10.1046/j.1365-2141.1998.00771.x [doi]
PST - ppublish
SO  - Br J Haematol. 1998 Jun;101(4):756-65. doi: 10.1046/j.1365-2141.1998.00771.x.